C12Y 113/11052
Indoleamine 2,3-dioxygenase , i.e. indoleamine 2,3-dioxygenase 1
Official title: Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1
C12Y113/11052 (Indoleamine 2,3-dioxygenase , i.e. indoleamine 2,3-dioxygenase 1) appears on 39 US grants and 71 published applications in this corpus.
Search patents in C12Y- Granted patents
- 39
- Published applications
- 71
- Assignees
- 39
- Inventors
- 121
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 2 |
| 2011 | 1 | 4 |
| 2012 | 2 | 0 |
| 2013 | 1 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 4 | 1 |
| 2017 | 1 | 5 |
| 2018 | 1 | 2 |
| 2019 | 3 | 6 |
| 2020 | 2 | 9 |
| 2021 | 2 | 10 |
| 2022 | 4 | 7 |
| 2023 | 13 | 7 |
| 2024 | 1 | 8 |
| 2025 | 2 | 5 |
| 2026 | 2 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Exon skipping by peptide nucleic acid derivatives12 May 2026US 12,624,068 B2OliPass Corporation
- Persistent memory T-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways24 Mar 2026US 12,582,709 B2The Regents of the University of California
- Indoleamine 2,3-dioxygenase based immunotherapy25 Feb 2025US 12,233,103 B2IO Biotech ApS
- Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)4 Feb 2025US 12,216,122 B2Regeneron Pharmaceuticals, Inc.
- Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators13 Feb 2024US 11,896,615 B2Juno Therapeutics, Inc.
- Liposome-based drug carrier for immune anticancer therapy and method for producing same9 Jul 2026US 2026/0191986 A1Konkuk University Industrial Cooperation Corp.
- Cells with increased immuno-regulatory properties and methods for their use and manufacture30 Oct 2025US 2025/0333702 A1Children's Medical Center Corporation
- Nucleotide delivery of cancer therapy23 Oct 2025US 2025/0327041 A1IO Biotech ApS
- Indoleamine 2,3-dioxygenase based immunotherapy16 Oct 2025US 2025/0319159 A1IO Biotech ApS
- Co-assembled peptide granules for intracellular protein delivery7 Aug 2025US 2025/0250297 A1University of Florida Research Foundation, Inc.
Most cited
By later US patents
- Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy44US 9,453,227 B2City of Hope · 2016
- Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy11US 10,100,314 B2City of Hope · 2018
- Checkpoint blockade and microsatellite instability10US 10,934,356 B2The Johns Hopkins University · 2021
- Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy8US 10,584,339 B2City of Hope · 2020
- Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy6US 10,961,538 B2City of Hope · 2021